We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+16.29%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.46B
AUM Growth
-$440K
Cap. Flow
-$163M
Cap. Flow %
-11.2%
Top 10 Hldgs %
60.09%
Holding
84
New
10
Increased
23
Reduced
32
Closed
17

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$24.1M
2
ZIMV
ZimVie
ZIMV
+$23.4M
3
FTRE icon
Fortrea Holdings
FTRE
+$10.8M
4
SNDX icon
Syndax Pharmaceuticals
SNDX
+$10.2M
5
BHC icon
Bausch Health
BHC
+$10.1M

Top Sells

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$44.6M
2
UTHR icon
United Therapeutics
UTHR
+$35.3M
3
NTRA icon
Natera
NTRA
+$34.8M
4
TEVA icon
Teva Pharmaceuticals
TEVA
+$26M
5
NVO
Novo Nordisk
NVO
+$21M

Sector Composition

Rank Sector Weight
1 Healthcare 89.3%
2 Miscellaneous 10.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MYGN icon
76
Myriad Genetics
MYGN
$302M
– –
-181,961
Closed -$4.45M
NVO
77
Novo Nordisk
NVO
$202B
– –
-146,956
Closed -$21M
OSCR icon
78
Oscar Health
OSCR
$9.4B
– –
-310,893
Closed -$4.92M
PCVX icon
79
Vaxcyte
PCVX
$8.9B
– –
-96,089
Closed -$7.26M
TERN
80
DELISTED
Terns Pharmaceuticals
TERN
– –
-286,266
Closed -$1.95M
VKTX icon
81
Viking Therapeutics
VKTX
$3.75B
– –
-138,489
Closed -$7.34M
XBI icon
82
State Street SPDR S&P Biotech ETF
XBI
$11.3B
– –
-100,000
Closed -$9.27M
GTHX
83
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
– –
-199,963
Closed -$456K
CERE
84
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
– –
-110,010
Closed -$4.5M
1 2 3
4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q3 2024 Portfolio in Review

As of Q3 2024, Eversept Partners held 84 positions worth $1.46B, down 0.03% from $1.46B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Eversept Partners withdrew a net $163M in Q3 2024, closing 17 positions and reducing 32 holdings. Its most notable exit was Novo Nordisk, an estimated $21M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, up from 89% a quarter earlier, followed by Miscellaneous.

Against the trend, Eversept Partners opened a new position in Fortrea Holdings worth $9.16M.

  • Eversept Partners's largest Q3 2024 buy was Fortrea Holdings: 457,967 shares worth $9.16M.
  • Eversept Partners added most to GSK in Q3 2024, an estimated $24.1M increase.
  • Eversept Partners's biggest Q3 2024 reduction was Inspire Medical Systems, cutting an estimated $44.6M.
  • Eversept Partners fully exited Novo Nordisk in Q3 2024, selling an estimated $21M.
  • Eversept Partners's ten largest holdings make up 60% of its $1.46B portfolio in Q3 2024.
  • Eversept Partners opened 10 new positions and closed 17 in Q3 2024.
  • Eversept Partners's portfolio value fell 0.03% quarter-over-quarter to $1.46B.

Based on Eversept Partners's 13F filing for Q3 2024, filed 14 Nov 2024.